F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
Le Lézard

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced that the final ...

Booster shots reduce the risks of COVID-19 deaths, study finds

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the ...

FDA reverses course and will review Moderna’s mRNA-based flu shot

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further studies. Federal officials did not immediately comment.